These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36308485)

  • 21. Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases.
    Upadhyay R; Klamer BG; Perlow HK; White JR; Bazan JG; Jhawar SR; Blakaj DM; Grecula JC; Arnett A; Mestres-Villanueva MA; Healy EH; Thomas EM; Chakravarti A; Raval RR; Lustberg M; Williams NO; Palmer JD; Beyer SJ
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of EGFR-TKI use on clinical outcomes of lung adenocarcinoma patients with brain metastases after Gamma Knife radiosurgery: a propensity score-matched analysis based on extended JLGK0901 dataset (JLGK0901-EGFR-TKI).
    Yomo S; Serizawa T; Yamamoto M; Higuchi Y; Sato Y; Shuto T; Akabane A; Jokura H; Kawagishi J; Aoyama H
    J Neurooncol; 2019 Oct; 145(1):151-157. PubMed ID: 31487030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Staged radiosurgery alone versus postoperative cavity radiosurgery for patients with midsize-to-large brain metastases: a propensity score matching analysis.
    Yomo S; Yako T; Kitazawa K; Oguchi K
    J Neurosurg; 2022 Aug; 137(2):555-562. PubMed ID: 34920421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncologic Outcome and Immune Responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding Timing and Benefiting Subgroups.
    Trommer M; Adams A; Celik E; Fan J; Funken D; Herter JM; Linde P; Morgenthaler J; Wegen S; Mauch C; Franklin C; Galldiks N; Werner JM; Kocher M; Rueß D; Ruge M; Meißner AK; Baues C; Marnitz S
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Safety and Efficacy of Concurrent Immune Checkpoint Blockade and Stereotactic Radiosurgery Therapy with Practitioner and Researcher Recommendations.
    Mehkri Y; Windermere SA; Still MEH; Yan SC; Goutnik M; Melnick K; Doonan B; Ghiaseddin AP; Rahman M
    World Neurosurg; 2024 Jan; 181():e133-e153. PubMed ID: 37739175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stereotactic radiosurgery for intracranial hemangiopericytomas: a multicenter study.
    Cohen-Inbar O; Lee CC; Mousavi SH; Kano H; Mathieu D; Meola A; Nakaji P; Honea N; Johnson M; Abbassy M; Mohammadi AM; Silva D; Yang HC; Grills I; Kondziolka D; Barnett GH; Lunsford LD; Sheehan J
    J Neurosurg; 2017 Mar; 126(3):744-754. PubMed ID: 27104850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis.
    Kotecha R; Kim JM; Miller JA; Juloori A; Chao ST; Murphy ES; Peereboom DM; Mohammadi AM; Barnett GH; Vogelbaum MA; Angelov L; Suh JH; Ahluwalia MS
    Neuro Oncol; 2019 Aug; 21(8):1060-1068. PubMed ID: 30796838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
    Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
    J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
    Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M
    BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
    Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP
    J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Local and distant brain control in melanoma and NSCLC brain metastases with concurrent radiosurgery and immune checkpoint inhibition.
    Le A; Mohammadi H; Mohammed T; Burney H; Zang Y; Frye D; Shiue K; Lautenschlaeger T; Miller J
    J Neurooncol; 2022 Jul; 158(3):481-488. PubMed ID: 35641840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined stereotactic radiosurgery and tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone for the treatment of non-small cell lung cancer patients with brain metastases.
    Chiou GY; Chiang CL; Yang HC; Shen CI; Wu HM; Chen YW; Chen CJ; Luo YH; Hu YS; Lin CJ; Chung WY; Shiau CY; Guo WY; Pan DH; Lee CC
    J Neurosurg; 2022 Aug; 137(2):563-570. PubMed ID: 34920439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent Administration of Immune Checkpoint Inhibitors and Single Fraction Stereotactic Radiosurgery in Patients With Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma Brain Metastases.
    Lehrer EJ; Kowalchuk RO; Gurewitz J; Bernstein K; Kondziolka D; Niranjan A; Wei Z; Lunsford LD; Fakhoury KR; Rusthoven CG; Mathieu D; Trudel C; Malouff TD; Ruiz-Garcia H; Bonney P; Hwang L; Yu C; Zada G; Patel S; Deibert CP; Picozzi P; Franzini A; Attuati L; Prasad RN; Raval RR; Palmer JD; Lee CC; Yang HC; Harmsen WS; Jones BM; Sharma S; Ahluwalia MS; Sheehan JP; Trifiletti DM
    Int J Radiat Oncol Biol Phys; 2023 Jul; 116(4):858-868. PubMed ID: 36690161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery.
    Tang JD; Mills MN; Nakashima J; Dohm AE; Khushalani NI; Forsyth PA; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Liu JKC; Ahmed KA
    J Neurooncol; 2024 Feb; 166(3):431-440. PubMed ID: 38310157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of stereotactic radiosurgery with and without whole-brain radiotherapy for the treatment of newly diagnosed brain metastases.
    Hall MD; McGee JL; McGee MC; Hall KA; Neils DM; Klopfenstein JD; Elwood PW
    J Neurosurg; 2014 Dec; 121 Suppl():84-90. PubMed ID: 25434941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic grading system specifically for elderly patients with brain metastases after stereotactic radiosurgery: a 2-institution study.
    Yamamoto M; Serizawa T; Higuchi Y; Nagano O; Aiyama H; Koiso T; Watanabe S; Kawabe T; Sato Y; Kasuya H
    J Neurosurg; 2018 Dec; 129(Suppl1):95-102. PubMed ID: 30544299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases.
    Lwu S; Goetz P; Monsalves E; Aryaee M; Ebinu J; Laperriere N; Menard C; Chung C; Millar BA; Kulkarni AV; Bernstein M; Zadeh G
    Oncol Rep; 2013 Feb; 29(2):407-12. PubMed ID: 23151681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases.
    Hirata M; Yasui K; Oota N; Ogawa H; Onoe T; Maki S; Ito Y; Hayashi K; Asakura H; Murayama S; Mitsuya K; Deguchi S; Nakamura K; Hayashi N; Nishimura T; Harada H
    Radiat Oncol; 2022 Dec; 17(1):213. PubMed ID: 36578021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stereotactic radiosurgery for brain metastases: a case-matched study comparing treatment results for patients 80 years of age or older versus patients 65-79 years of age.
    Watanabe S; Yamamoto M; Sato Y; Kawabe T; Higuchi Y; Kasuya H; Yamamoto T; Matsumura A; Barfod BE
    J Neurosurg; 2014 Nov; 121(5):1148-57. PubMed ID: 25061863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.